Out-Licensing Agreements (Tables)

9 Months Ended

Sep. 30, 2022

Out-licensing Agreements

Schedule of deferred revenue in connection with collaboration agreements

	Balance at						Balance at End
	Beginning of Period		Additions		Deductions		of Period
Nine Months Ended September 30, 2022
Huadong rilonacept	$	—	$	12,000	$	—	$	12,000
Genentech vixarelimab		—		14,290		—		14,290
Deferred revenue	$	—	$	26,290	$	—	$	26,290